Latest Lentigen Corporation Stories
GAITHERSBURG, Md., Feb. 13, 2013 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced today that that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to P140K methylguanine methyltransferase (MGMT) transduced human CD34 cells (product name: LG631-CD34) for bone marrow protection in the treatment of glioblastoma multiforme. Orphan drug designation...
CLEVELAND and GAITHERSBURG, Md., Nov. 14, 2011 /PRNewswire/ -- University Hospitals (UH) Case Medical Center, Case Western Reserve University School of Medicine and Lentigen Corporation announced today the initiation of a novel Phase I clinical trial of LG631 gene therapy for the protection of hematopoietic stem cells (HSCs) from the dose limiting toxicity of chemotherapy with Temodar. Approximately 17,000 Americans are diagnosed with glioblastoma every year and only two percent of them...
GAITHERSBURG, Md., Nov. 3, 2010 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced today that it will receive $1,235,306 in cash grants from the U.S. Government under the Patient Protection and Affordable Care Act. Only companies with no more than 250 employees were eligible. Qualifying projects had to show reasonable potential to result in new therapies to treat areas of unmet medical...
GAITHERSBURG, Md., Aug. 9 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) Small Business Innovation Research grant (SBIR) for a program on "Clinical Vector for TCR Immunotherapy Targeted to Melanoma". In this program, Lentigen will collaborate with Dr. Michael Nishimura, Professor of Surgery, at the Medical...
GAITHERSBURG, Md., May 18 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) small business technology transfer (STTR) grant for a program on "Lentiviral Gene Therapy for Mucopolysaccharidosis." In this program, Lentigen will collaborate with Dr. R. Scott McIvor Professor, Department of Genetics, Cell Biology and...
NEW YORK and GAITHERSBURG, Md., April 22 /PRNewswire/ -- The International AIDS Vaccine Initiative (IAVI) and Lentigen today announced a collaboration to design a preventive AIDS vaccine based on Lentigen's technology. The candidate AIDS vaccine will be devised to safely mimic biological aspects of HIV infection and tested first in pre-clinical studies as part of an initial 18-month agreement. Lentigen's technology relies on a synthetic version of a virus related to HIV that has been...
GAITHERSBURG, Md,, Dec. 9 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) small business innovation research (SBIR) grant for a program on "A Novel Method of Generating Hepatitis C Virus-Like Particles using Lentivirus". In this program, Lentigen will collaborate with Epixis SA (Paris, France). The Hepatitis C...
GAITHERSBURG, Md. and ATLANTA, Feb 4 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, and Expression Therapeutics, a biotechnology company specializing in factor VIII-based therapeutics, today announced a collaborative agreement to co-develop novel cell and protein therapies for Hemophilia A. Hemophilia A is an inherited blood clotting disorder caused by a mutation in the factor VIII gene...
Partnership will accelerate research of potential vaccine for low-resource countries SEATTLE, and GAITHERSBURG, Md., Dec. 4 /PRNewswire/ -- The biotech company Lentigen Corporation and the nonprofit global health organization PATH announced today a partnership to accelerate research on a pandemic influenza vaccine. PATH will initially invest $3 million over 27 months and work with Lentigen on early-stage development of a H5N1 virus-like particle (VLP) prototype pandemic influenza vaccine....
